ScholarIQanswers from OpenAlex & ORCID
D. Craig Allred
ResearcherPublications, citations & collaboration network
D. Craig Allred is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does D. Craig Allred have?
ScholarIQindexed works
D. Craig Allred has 270 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does D. Craig Allred have?
ScholarIQcitation count
D. Craig Allred has 48,844 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of D. Craig Allred?
ScholarIQh-index
D. Craig Allred has an h-index of 90 in OpenAlex.
What is the i10-index of D. Craig Allred?
ScholarIQi10-index
D. Craig Allred has an i10-index of 168 in OpenAlex.
What is the OpenAlex record for D. Craig Allred?
ScholarIQopenalex
The OpenAlex for D. Craig Allred is on the source record.
What are the most-cited papers on D. Craig Allred?
ScholarIQmost cited works
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain, William E. Barlow, Steven Shak, Gabriel N. Hortobágyi, Robert B. Livingston, I‐Tien Yeh, Peter M. Ravdin, Roberto Bugarini, Frederick L. Baehner, Nancy E. Davidson, George W. Sledge, Eric P. Winer, Clifford A. Hudis, James N. Ingle, Edith A. Perez, Kathleen I. Pritchard, Lois E. Shepherd, Julie R. Gralow, Carl Yoshizawa, D. Craig Allred, C. Kent Osborne, Daniel F. Hayes
Prognostic Factors in Breast Cancer
Patrick L. Fitzgibbons, David L. Page, Donald L. Weaver, Ann D. Thor, D. Craig Allred, Gary M. Clark, Stephen G. Ruby, Frances P. O’Malley, Jean F. Simpson, James L. Connolly, Daniel F. Hayes, Stephen B. Edge, Allen S. Lichter, Stuart J. Schnitt
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian Andrew Van Tine, Jeremy Hoog, Reece Goiffon, Theodore C. Goldstein, Sam Ng, Lin Li, Robert J. Crowder, Jacqueline Snider, Karla V. Ballman, Jason D. Weber, Ken Chen, Daniel C. Koboldt, Cyriac Kandoth, William Schierding, Joshua F. McMichael, Christopher A. Miller, Charles Lu, Christopher Harris, Michael D. McLellan, Michael C. Wendl, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie A. Margenthaler, Gildy V. Babiera, P. Kelly Marcom, J. Michael Guenther, Marilyn Leitch, Kelly K. Hunt, John A. Olson, Tao Yu, Christopher A. Maher, Lucinda Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica‐Worms, Sandra McDonald, Mark A. Watson, David J. Dooling, David M. Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica‐Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson